LIC Mutual Fund Pharma Fund - Regular Plan - Growth

LIC Mutual Fund Pharma Fund - Regular Plan - Growth investment objective and strategy

LIC Mutual Fund Pharma Fund - Regular Plan - Growth ka main objective hai pharma sector mein long-term capital appreciation dena. Ye fund un investors ke liye suitable hai jo high growth potential wale stocks mein invest karna chahte hain. Iska investment style growth-oriented hai, jismein fund manager Yogesh Patil actively stock selection karte hain. Yadi aap equity mutual funds mein invest karne ki soch rahe hain, toh ye fund aapke portfolio mein diversification la sakta hai. Pharma sector ki growth potential ko dhyan mein rakhte hue, ye fund aise stocks mein invest karta hai jo future mein achhe returns de sakte hain. Fund ka focus hai quality companies par, jaise ki Sun Pharmaceutical aur Dr. Reddy's, jo sector mein established players hain. Chaliye, iske risk aur downside ko samajhte hain.

LIC Mutual Fund Pharma Fund - Regular Plan - Growth historical performance and returns

Ab hum is fund ki historical performance par nazar daalte hain. LIC Mutual Fund Pharma Fund - Regular Plan - Growth ne pichle 1 saal mein -3.89% return diya hai, jabki 3 saal mein iska return 4.01% aur 5 saal mein 3.71% raha hai. Ye returns kaafi volatility ke sath aate hain, jo pharma sector ki inherent nature hai. Aayiye, is fund ki performance ko benchmark Nifty Pharma TRI se compare karte hain:

Period	LIC Mutual Fund Pharma Fund - Regular Plan - Growth Returns (%)	Benchmark Returns (%)
1 Year	-3.89%	Data Not Available
3 Years	4.01%	Data Not Available
5 Years	3.71%	Data Not Available

Fund manager Yogesh Patil ka experience is fund ki performance par kafi impact dalta hai. Unhone apni tenure mein fund ko strategically manage kiya hai. Lekin, volatility aur market conditions ko dekhte hue, investors ko is fund mein invest karne se pehle apne goals aur risk appetite ko samajhna hoga.

LIC Mutual Fund Pharma Fund - Regular Plan - Growth top holdings and portfolio allocation

LIC Mutual Fund Pharma Fund - Regular Plan - Growth ki portfolio allocation kaafi interesting hai. Is fund ki top holdings mein kuch established companies hain, jaise:

• Sun Pharmaceutical Industries Ltd. - 20.5%
• Dr. Reddy's Laboratories Ltd. - 12.8%
• Cipla Ltd. - 10.4%
• Divi's Laboratories Ltd. - 9.8%
• Torrent Pharmaceuticals Ltd. - 7.2%

Is fund ka total AUM ₹4500 Cr hai, jo iski popularity aur investor trust ko dikhata hai. Ye sector-specific allocation pharma sector ki growth potential aur demand ko dhyan mein rakhte hue kiya gaya hai. Is fund ki investment strategy quality stocks par focus karna hai, jo long-term mein sustainable growth de sakte hain. Investors ko ye dekhna chahiye ki in top holdings ka performance market conditions ke sath kaisa hai, kyunki sector volatility se affect ho sakta hai. Isliye, yeh zaroori hai ki investors apne portfolio ko diversify karte rahein. Chaliye, ab hum iski risk profile ko samajhte hain.

LIC Mutual Fund Pharma Fund - Regular Plan - Growth riskometer and downside risk

LIC Mutual Fund Pharma Fund - Regular Plan - Growth ka riskometer "Very High" hai. Iska matlab hai ki yeh fund high-risk investors ke liye suitable hai. Pharma sector mein volatility hoti hai, aur iske returns bhi kabhi-kabhi fluctuate karte hain. Agar aapne socha hoga ki yeh fund aapke liye hai, toh zaroori hai ki aap apni risk tolerance ko samjhein. Yadi aapko high volatility se dar nahi hai aur aap long-term ki soch rakhte hain, toh yeh fund aapke liye beneficial ho sakta hai. Fund ka expense ratio 1.95% hai, jo is fund ko thoda expensive banata hai, lekin high growth potential ke sath yeh justify hota hai. Isliye, aapko apne overall portfolio ke hisaab se is fund ka selection karna chahiye. Chaliye, ab is fund ke long-term investment outlook par ek nazar daalte hain.

• Pros:
  • High growth potential in the pharma sector.
  • Experienced fund manager with a good track record.
  • Diversification through sector-specific investments.
  • Long-term capital appreciation potential.
• Cons:
  • High risk due to market volatility.
  • Expense ratio is comparatively high.
  • Recent underperformance in the short term.